Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia

Centre Hospitalier Universitaire de Nīmes

Overview

To date there is no brain imaging and olfactory data available in COVID-19 positive patients with anosmia. By describing the pathophysiological characteristics underlying the olfactory symptoms and clinical characteristics of COVID-19 infection, the study investigators wish to compare the MRI aspects obtained in COVID-19 patients with and without anosmia, in the absence of other underlying neurological disorders.

Brain mapping of COVID-19 patients with or without anosmia will allow better understanding of the mechanisms leading to the onset of these symptoms and will provide a pathophysiological basis for the therapeutic interventions to improve the clinical prognosis of affected patients. The study investigators hypothesize that in COVID-19 patients witch anosmia the brain mapping objectified by an MRI examination is modified and that there are functional abnormalities in the brain in these patients.

Study Type

OBSERVATIONAL

Conditions

Covid-19 Anosmia

Interventions

Brain MRI scanOTHER

Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive adult patients consulting the CAREB or hospitalized at the Nîmes teaching hospital due to COVID-19 infection (fever, persistent cough, tiredness, shortness of breath, diarrhea, abdominal pain, chest pain, sore throat, loss of smell or taste) * COVID-19 confirmed by RT-PCR and / or chest CT or clinical characteristics (i.e an epidemic history and 2 clinical manifestations or at least 3 clinical manifestations) * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan "with anosmia" group: * scoring \< 30 on a VAS 0-100 for olfactory ability * Responding "yes" to question "have you lost your sense of smell in the last few days?" * Negative result to olfactory test with n-Butanol diluted to 1/1000. "without anosmia" group: * scoring \< 80 on a VAS 0-100 for olfactory ability * Responding "no" to question "have you lost your sense of smell in the last few days?" * Positive result to olfactory test with n-Butanol diluted to 1/16000. Exclusion Criteria: * Patient suffering from serious medical problems or hospitalized in an intensive care unit for invasive ventilation or severe dyspnea. * Patient with neurological (motor, sensitive or cognitive), neuropsychiatric or vascular disorders. * Patient with a contraindication to MRI (pace maker, claustrophobic patient, metallic heart valve, etc.). * Patient with a history of rhinological pathology or a sense of smell problem. * Patient with known neurological, psychiatric or neuroradiological manifestation.The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * The subject is unable to express consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Patient is pregnant, parturient or breastfeeding

Locations (1)

CHU de Nimes

Nîmes, France

Outcomes

Primary Outcomes

Brain regional homogeneity between COVID-19 patients with and without anosmia

MRI; Voxels

Time frame: Day 0

Secondary Outcomes

Brain regional homogeneity between COVID-19 patients with and without anosmia

MRI; Voxels

Time frame: Month 3

Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia

MRI; Voxels

Time frame: Day 0

Fractional anisotropy between COVID-19 patients with and without anosmia

MRI; voxels, value between 0-1

Time frame: Day 0

Fractional anisotropy between COVID-19 patients with and without anosmia

MRI; voxels, value between 0-1

Time frame: Month 3

Mean diffusivity between COVID-19 patients with and without anosmia

MRI; mm2/s

Time frame: Day 0

Mean diffusivity between COVID-19 patients with and without anosmia

MRI; mm2/s

Time frame: Month 3

Radial diffusivity between COVID-19 patients with and without anosmia

MRI; mm2/s

Time frame: Day 0

Radial diffusivity between COVID-19 patients with and without anosmia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.